BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14593855)

  • 1. Clinical studies of camptothecin and derivatives.
    Soepenberg O; Sparreboom A; Verweij J
    Alkaloids Chem Biol; 2003; 60():1-50. PubMed ID: 14593855
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical trials using irinotecan.
    Houghton PJ; Santana VM
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
    [No Abstract]   [Full Text] [Related]  

  • 5. Topoisomerase I inhibitors: topotecan and irenotecan.
    Creemers GJ; Lund B; Verweij J
    Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
    [No Abstract]   [Full Text] [Related]  

  • 6. [The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
    Lavergne O; Bigg DC
    Bull Cancer; 1998 Dec; Spec No():51-8. PubMed ID: 9932086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of camptothecin analogs in childhood cancers.
    Bomgaars L; Berg SL; Blaney SM
    Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
    Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of the topoisomerase I inhibitors.
    Seiter K
    Expert Opin Drug Saf; 2005 Jan; 4(1):45-53. PubMed ID: 15709897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase I inhibitors.
    Takimoto CH; Kieffer LV; Arbuck SG
    Cancer Chemother Biol Response Modif; 1997; 17():80-113. PubMed ID: 9551210
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel camptothecin derivatives.
    Legarza K; Yang LX
    In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 13. Design, synthesis and development of novel camptothecin drugs.
    Liew ST; Yang LX
    Curr Pharm Des; 2008; 14(11):1078-97. PubMed ID: 18473856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the clinical experience with irinotecan (CPT-11).
    Horowitz RW; Wadler S; Wiernik PH
    Am J Ther; 1997; 4(5-6):203-10. PubMed ID: 10423612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in topoisomerase I-targeting agents, camptothecin analogues.
    Kim DK; Lee N
    Mini Rev Med Chem; 2002 Dec; 2(6):611-9. PubMed ID: 12370044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase I inhibitors: topotecan and irinotecan.
    Jones SF; Burris HA
    Cancer Pract; 1996; 4(1):51-3. PubMed ID: 8788772
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent clinical advances with camptothecin analogues.
    Slichenmyer WJ; Donehower RC
    Cancer Treat Res; 1995; 78():29-43. PubMed ID: 8595145
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.